Skip to main content
Bio-Thera Solutions, Ltd. logo

Bio-Thera Solutions, Ltd. — Investor Relations & Filings

Ticker · 688177 ISIN · CNE100003R98 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 691 across all filing types
Latest filing 2022-04-28 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688177

About Bio-Thera Solutions, Ltd.

https://www.bio-thera.com/

Bio-Thera Solutions, Ltd. is a biopharmaceutical company dedicated to the research and development of innovative therapeutics and high-quality biosimilars. The company focuses on addressing serious medical conditions across oncology, autoimmune, and cardiovascular therapeutic areas. Its portfolio includes several approved biosimilars, such as QLETLI (adalimumab), POBEVCY (bevacizumab), and TOFIDENCE (tocilizumab), alongside a robust pipeline of novel drug candidates, including antibody-drug conjugates (ADCs) and monoclonal antibodies. Bio-Thera utilizes advanced technology platforms to streamline the drug discovery and development process, aiming to expand global access to essential biologic medicines. The organization maintains a commitment to rigorous clinical standards and international regulatory compliance to deliver effective treatment options for patients worldwide.

Recent filings

Filing Released Lang Actions
中国国际金融股份有限公司关于百奥泰生物制药股份有限公司2021年度募集资金存放与使用情况的专项核查报告
Audit Report / Information Classification · 95% confidence The document is a detailed report on the storage and usage of funds raised by 百奥泰生物制药股份有限公司 in 2021, including amounts raised, usage breakdown, management of funds, and compliance with regulatory requirements. It includes audit opinions from an accounting firm and verification by the sponsoring institution. The content focuses on the specific use and management of raised capital, consistent with a specialized audit or verification report rather than a full annual report or earnings release. The document is not a simple announcement or certification but contains substantive financial and operational details about fundraising and fund usage. Therefore, it fits the category of an Audit Report / Information (AR), which covers standalone audit reports and results of internal or regulatory checks related to fundraising and capital use.
2022-04-28 Chinese
百奥泰2021年年度报告摘要
Annual Report Classification · 100% confidence The document is titled as the "2021 年年度报告摘要" which translates to "2021 Annual Report Summary". It contains detailed information about the company's business, industry, financial data for multiple years including 2021, 2020, and 2019, quarterly financial data for 2021, shareholder information, and extensive discussion on business operations, products, and industry context. The length is substantial (15,000 characters), and it includes actual financial figures and management discussion. This matches the characteristics of an Annual Report (10-K) rather than a brief announcement or a presentation. Therefore, the document is classified as an Annual Report (10-K).
2022-04-28 Chinese
独立董事提名人声明（Henry Wei （魏亨利））
Regulatory Filings
2022-04-28 Chinese
独立董事候选人声明（黄德汉）
Regulatory Filings
2022-04-28 Chinese
独立董事候选人声明（Henry Wei （魏亨利））
Regulatory Filings
2022-04-28 Chinese
百奥泰 第一届监事会第二十三次会议决议的公告
Regulatory Filings Classification · 95% confidence The document is an announcement of resolutions passed at the 23rd meeting of the first Supervisory Board of 百奥泰生物制药股份有限公司. It includes approvals of various reports such as the 2021 Annual Report, 2022 Q1 Report, 2021 Supervisory Board Work Report, 2021 Internal Control Evaluation Report, 2021 Financial Final Report, and others. However, the document itself does not contain the full reports or detailed financial data but rather states that the full reports are published on the Shanghai Stock Exchange website and other media. The document is relatively short (3897 characters) and serves as a formal announcement of the meeting decisions and approvals, not the reports themselves. Therefore, according to the MENU VS MEAL RULE, this document is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement of meeting resolutions and approvals referencing other reports rather than the reports themselves.
2022-04-28 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.